By using a combinational therapeutic strategy, a research team have created a promising approach to combat chemoresistance in GBM. Glioblastoma often resists front-line chemotherapies, including temozolomide, a drug that damages DNA and triggers tumour cell death. Nearly half of glioblastoma patients resist the treatment by producing a DNA-repairing enzyme, MGMT, but until recently it wasn’t clear why temozolomide wasn’t working for patients who lacked the MGMT enzyme.
Using glioblastoma cell lines and primary glioblastoma cells derived from patient tumour specimens the team discovered that inhibiting two specific proteins when combined with temozolomide, produced an effective “triple combinational therapy” that overcame chemoresistance.
The findings from this three-pronged approach to treating glioblastoma are published this week in Oncogenesis.